A Phase II Immunotherapeutic Trial: Combination Androgen Ablative Therapy and CTLA-4 Blockade as a Treatment for Advanced Prostate Cancer
Abstract
The induction of tumor-specific T cells remains a primary obstacle to immunotherapeutic approaches for most cancers including prostate cancer. This difficulty has been largely ascribed to mechanisms for tumor evasion of the immune system and host-imposed restrictions (collectively referred to as tolerance) that prevent cross-reactive autoimmunity against the parent tissues from which tumors arise. Limitations in techniques to identify novel and truly immunogenic prostate-specific antigens and efficient methods to modify autologous tissues for vaccine preparation have further constrained approaches to develop immune-based therapies for prostate cancer. Hence, relatively straightforward manipulations that induce specific T cell responses against prostate tumors or epithelial tissues, especially in vivo, might ultimately prove valuable for prostate cancer immunotherapy. This study explores combined androgen ablation (AA) + CTLA-4 blockade immunotherapy as a means of potentiating T cell-mediated responses against prostate tumors to improve overall treatment of advanced prostate cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Dec 01, 2003
- Accession Number
- ADA425731
Entities
People
- Eugene D. Kwon
Organizations
- Mayo Clinic